Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
After recently gaining recognition as the first professional Santa Claus with Down syndrome in the US,...
US healthcare officials recently said a food-poisoning outbreak tied to alfalfa sprouts and involving multiple germs...
Common personal care products widely contain unlabeled toxic chemicals, results from a new peer-reviewed study suggest....
